Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 16, 2021

Primary Completion Date

May 23, 2022

Study Completion Date

June 22, 2022

Conditions
Metabolic Acidosis
Interventions
DRUG

Meglumine Sodium Succinate

500 ml of 1.4% solution IV at a rate of at least 4 ml and not more than 10 ml per minute

DRUG

Placebo

Ringer's solution, 500 ml IV at a rate of at least 4 ml and not more than 10 ml per minute

Trial Locations (6)

152040

Ivanovo Regional Clinical Hospital, Ivanovo

163001

"GBUZ Arkhangelsk region First GKB named after E.E. Volosevich", Arkhangelsk

430005

National Research Mordovian State University n.a. N.P. Ogarev, Saransk

603001

Privolzhsky District Medical Center, Nizhny Novgorod

Unknown

Central Clinical Hospital with a polyclinic of the Office of the President of the Russian Federation, Moscow

Saint-Petersburg I.I.Dzanelidze Research Institute of Emergency Medicine, Saint Petersburg

All Listed Sponsors
collaborator

Atlant Clinical Ltd.

OTHER

lead

POLYSAN Scientific & Technological Pharmaceutical Company

INDUSTRY

NCT05147051 - Meglimine Sodium Succinate for Correction of Metabolic Acidosis in Critically Ill Patients | Biotech Hunter | Biotech Hunter